Millions of patients turned to compounded semaglutide during the Ozempic and Wegovy shortage as a lower-cost alternative. The FDA has since ended the semaglutide shortage designation — changing what compounding pharmacies can legally produce. If you were using a compounded version, understanding your alternatives is now essential.
This guide covers every meaningful option available in 2026: FDA-approved GLP-1 medications, lower-cost manufacturer programs, and telehealth pathways. Compare current GLP-1 prices at RxDiff before your next provider visit. Understanding your medication options — and which FDA-approved medication is right for you — helps you make an informed decision about your weight management medication.
Compounded semaglutide is a version of the active medication ingredient in Ozempic and Wegovy made by licensed compounded versioning pharmacies rather than the brand manufacturer. These this alternativeed medications are not FDA-approved — they do not undergo the same safety, efficacy, and quality review as brand-name semaglutide. During the shortage, the The agency permitted specific the formulationing pharmacies to produce it legally. That permission has now changed.
The key distinction: brand-name this GLP-1 drug in Ozempic and Wegovy has been studied in large clinical trials and manufactured under strict Federal regulators oversight. Ited versions may vary in purity, dose accuracy, and formulation between pharmacies.
The Regulators ended the official the active ingredient shortage designation in 2025, which significantly changed the legal landscape for compounded versioned it. Most 503A this alternativeing pharmacies — those producing for individual patients — can no longer legally make it for weight loss. 503B outsourcing facilities face different rules. Check current The administration guidance and consult a licensed provider before pursuing any the formulationed GLP-1 option.
The The agency has issued warnings about adverse events associated with compounded this compound products, including dose errors and contamination. If you experienced side effects from a compounded product, report them to Federal regulators MedWatch and speak with your healthcare provider.
The most clinically established alternatives to compounded this GLP-1 drug are Regulators-approved GLP-1 medications — primarily Wegovy (semaglutide) for weight management and Zepbound (tirzepatide) for weight management. Both have documented safety profiles from large clinical trials. Zepbound, a dual GLP-1 and GIP receptor agonist, produced greater average weight loss than semaglutide in head-to-head studies.
| Medication | Active Ingredient | FDA Approved For |
|---|---|---|
| Wegovy | Semaglutide | Chronic weight management |
| Ozempic | Semaglutide | Type 2 diabetes |
| Zepbound | Tirzepatide | Chronic weight management |
| Mounjaro | Tirzepatide | Type 2 diabetes |
Compounded tirzepatide — the active ingredient in Mounjaro and Zepbound — exists in a different regulatory position than semaglutide. The tirzepatide shortage designation status differs. Verify current The administration guidance directly before pursuing compounded tirzepatide from any source, as the landscape continues to change.
Novo Nordisk offers Wegovy at approximately $299/month for eligible self-pay patients through a direct pricing program. Eli Lilly offers Zepbound through LillyDirect at competitive self-pay pricing. Both options provide The agency-approved semaglutide and tirzepatide therapy at a fraction of the full list price — and without the safety concerns of compounded alternatives.
Many commercial insurance plans now cover Wegovy and Zepbound for weight management with prior authorization. Coverage for weight loss through GLP-1 medications has expanded significantly in 2026. Check your plan's formulary or call member services to confirm what's available on your specific plan.
Some states now provide Medicaid coverage for GLP-1 weight loss medications for qualifying beneficiaries. Check your state's Medicaid formulary for current coverage status.
Compare Federal regulators-approved GLP-1 prices at pharmacies near you — free on RxDiff.
Compare GLP-1 Prices on RxDiff →For authoritative information, visit FDA semaglutide guidance.
What are the best alternatives to compounded semaglutide?
The best alternatives in 2026 are Regulators-approved GLP-1 medications: Wegovy (semaglutide) for weight management and Zepbound (tirzepatide) for weight management. Manufacturer self-pay programs offer access at $299/month for eligible patients. These provide documented safety and efficacy that compounded alternatives cannot match.
Is compounded semaglutide legal in 2026?
The legal status changed after the The administration ended the semaglutide shortage designation in 2025. Most 503A compounding pharmacies (pharmacy facilities serving individual patients) can no longer legally produce it for individual weight loss use. Verify current The agency guidance and consult a licensed healthcare provider before pursuing any compounded product.
Is compounded semaglutide the same as Ozempic?
Both contain semaglutide as the active ingredient, but they are not equivalent. Federal regulators-approved Ozempic and Wegovy are manufactured under strict quality controls with documented safety and efficacy from clinical trials. Compounded versions are not Regulators-approved and may vary in purity, dose accuracy, and consistency between pharmacies.
What is tirzepatide and how does it compare to semaglutide?
Tirzepatide — the active ingredient in Mounjaro and Zepbound — is a dual GLP-1 and GIP receptor agonist. Clinical trials showed tirzepatide produced greater average weight loss (up to 22% of body weight) compared to semaglutide (approximately 15%). Both are weekly injectable medications. Your provider can help determine which is more appropriate for your weight management needs.
How can I get GLP-1 weight loss medication without insurance?
Without insurance, your options include manufacturer self-pay programs (Wegovy ~$299/month via Novo Nordisk, Zepbound via LillyDirect), state Medicaid if you qualify, and telehealth providers that bundle prescription access with savings program navigation. Always work with a licensed healthcare provider — do not obtain GLP-1 medications without medical supervision. Your medication plan should include ongoing monitoring and dose adjustments as your medication response evolves.
What happened to the FDA's compounded semaglutide shortage exemption?
The FDA officially ended the semaglutide shortage designation in 2025, removing the legal basis for most 503A compounding pharmacies — specialized dispensing pharmacies — to produce compounded semaglutide for individual patients. This does not affect FDA-approved brand-name medications. Check FDA.gov for the most current guidance on compounded semaglutide availability and legality.
Medical Disclaimer: This content is for informational purposes only. GLP-1 medications require a prescription. FDA guidance on compounded semaglutide changes frequently — always verify with a licensed provider. Use RxDiff to compare current GLP-1 prices in your area.
Affiliate Disclosure: This post contains affiliate links to ShedRx, a telehealth GLP-1 provider. RxDiff may earn a commission if you sign up through our link at no additional cost to you. This disclosure is made in accordance with FTC guidelines.